Patents by Inventor Kenneth A. Stauderman

Kenneth A. Stauderman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRAC CHANNEL INHIBITOR COMPOSITIONS
    Publication number: 20240058332
    Abstract: Provided herein are pharmaceutical compositions, such as emulsions and nanosuspensions, comprising a CRAC channel inhibitor. Also provided herein are methods of treating pancreatitis, viral infections, stroke, traumatic brain injury, fibrosis, inflammation, and autoimmune diseases by administering such pharmaceutical compositions.
    Type: Application
    Filed: August 23, 2023
    Publication date: February 22, 2024
    Inventors: Kenneth A. STAUDERMAN, Michael DUNN
  • IMPROVED SYNTHESIS OF CRAC CHANNEL INHIBITORS
    Publication number: 20240010638
    Abstract: Provided herein is an improved synthetic method for the production of CRAC channel inhibitors. The synthetic method provides a method for producing highly pure CRAC channel inhibitors for clinical testing.
    Type: Application
    Filed: November 13, 2020
    Publication date: January 11, 2024
    Inventors: Kenneth STAUDERMAN, Michael DUNN, Kay OLMSTEAD
  • Pyrazine-containing compound
    Patent number: 11752148
    Abstract: Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: September 12, 2023
    Assignee: CALCIMEDICA, INC.
    Inventors: Gonul Velicelebi, Kenneth Stauderman, Michael Dunn, Jack Roos
  • METHODS AND COMPOSITIONS FOR TREATING ACUTE KIDNEY INJURY
    Publication number: 20230226058
    Abstract: Compositions and methods related to the treatment of acute kidney injury (AKI) through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to reduce inflammatory responses that may lead to AKI, or the progression of AKI to CKD.
    Type: Application
    Filed: November 18, 2022
    Publication date: July 20, 2023
    Inventors: Kenneth A. STAUDERMAN, Michael DUNN, Sudarshan HEBBAR, Rachel LEHENY
  • METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME
    Publication number: 20230120819
    Abstract: Compositions and methods related to the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) including viral pneumonia through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to reduce pro-inflammatory cytokine releases that may lead to ALI and/or ARDS.
    Type: Application
    Filed: March 19, 2021
    Publication date: April 20, 2023
    Inventors: Kenneth A. STAUDERMAN, Michael DUNN, Sudarshan HEBBAR, Rachel LEHENY
  • Pyrazine-containing compound
    Patent number: 11439639
    Abstract: Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: September 13, 2022
    Assignee: CALCIMEDICA, INC.
    Inventors: Gonul Velicelebi, Kenneth Stauderman, Michael Dunn, Jack Roos
  • PYRAZINE-CONTAINING COMPOUND
    Publication number: 20220265645
    Abstract: Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may he used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.
    Type: Application
    Filed: March 16, 2021
    Publication date: August 25, 2022
    Inventors: Gonul VELICELEBI, Kenneth STAUDERMAN, Michael DUNN, Jack ROOS
  • Pancreatitis treatment
    Patent number: 11311535
    Abstract: Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: April 26, 2022
    Assignee: CALCIMEDICA, INC.
    Inventors: Gonul Velicelebi, Kenneth Stauderman, Michael Dunn, Jack Roos
  • SYNTHESIS OF CRAC CHANNEL INHIBITORS
    Publication number: 20220056053
    Abstract: A convergent synthetic method for the production of CRAC channel inhibitors is described herein. The synthetic method provides a method for producing highly pure CRAC channel inhibitors for clinical testing.
    Type: Application
    Filed: November 4, 2021
    Publication date: February 24, 2022
    Inventors: Kenneth A. STAUDERMAN, Michael DUNN, Jeffrey P. WHITTEN, Evan ROGERS
  • PYRAZINE-CONTAINING COMPOUND
    Publication number: 20220000863
    Abstract: Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.
    Type: Application
    Filed: September 10, 2021
    Publication date: January 6, 2022
    Inventors: Gonul VELICELEBI, Kenneth STAUDERMAN, Michael DUNN, Jack ROOS
  • Pyrazine-containing compound
    Patent number: 11013737
    Abstract: Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: May 25, 2021
    Assignee: CALCIMEDIA, INC.
    Inventors: Gonul Velicelebi, Kenneth Stauderman, Michael Dunn, Jack Roos
  • Pyrazine-containing compound
    Patent number: 10973818
    Abstract: Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: April 13, 2021
    Assignee: CALCIMEDICA, INC.
    Inventors: Gonul Velicelebi, Kenneth Stauderman, Michael Dunn, Jack Roos
  • PYRAZINE-CONTAINING COMPOUND
    Publication number: 20210038597
    Abstract: Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.
    Type: Application
    Filed: October 22, 2020
    Publication date: February 11, 2021
    Inventors: Gonul VELICELEBI, Kenneth STAUDERMAN, Michael DUNN, Jack ROOS
  • PYRAZINE-CONTAINING COMPOUND
    Publication number: 20200368228
    Abstract: Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.
    Type: Application
    Filed: August 7, 2020
    Publication date: November 26, 2020
    Inventors: Gonul VELICELEBI, Kenneth STAUDERMAN, Michael DUNN, Jack ROOS
  • Pyrazine-containing compound
    Patent number: 10821109
    Abstract: Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: November 3, 2020
    Assignee: CALCIMEDICA, INC.
    Inventors: Gonul Velicelebi, Kenneth Stauderman, Michael Dunn, Jack Roos
  • CRAC CHANNEL INHIBITOR COMPOSITIONS
    Publication number: 20200253966
    Abstract: Provided herein are pharmaceutical compositions, such as emulsions and nanosuspensions, comprising a CRAC channel inhibitor. Also provided herein are methods of treating pancreatitis, viral infections, stroke, traumatic brain injury, fibrosis, inflammation, and autoimmune diseases by administering such pharmaceutical compositions.
    Type: Application
    Filed: January 26, 2018
    Publication date: August 13, 2020
    Inventors: Kenneth A. STAUDERMAN, Michael DUNN
  • CRAC CHANNEL INHIBITORS FOR THE TREATMENT OF STROKE AND TRAUMATIC BRAIN INJURY
    Publication number: 20200101069
    Abstract: Described herein are methods of treatment of stroke and traumatic brain injury comprising administration of a CRAC channel inhibitor.
    Type: Application
    Filed: August 8, 2019
    Publication date: April 2, 2020
    Inventors: Kenneth STAUDERMAN, Michael DUNN, Sudarshan HEBBAR, Midori YENARI, Rachid KACIMI
  • Use of CRAC channel inhibitors for the treatment of stroke and traumatic brain injury
    Patent number: 10478435
    Abstract: Described herein are methods of treatment of stroke and traumatic brain injury comprising administration of a CRAC channel inhibitor.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: November 19, 2019
    Assignees: CALCIMEDICA, INC., THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Kenneth Stauderman, Michael Dunn, Sudarshan Hebbar, Midori Yenari, Rachid Kacimi
  • Use of CRAC channel inhibitors for the treatment of stroke and traumatic brain injury
    Patent number: 10420766
    Abstract: Described herein are methods of treatment of stroke and traumatic brain injury comprising administration of a CRAC channel inhibitor.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: September 24, 2019
    Assignees: CALCIMEDICA, INC., THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Kenneth Stauderman, Michael Dunn, Sudarshan Hebbar, Midori Yenari, Rachid Kacimi
  • USE OF CRAC CHANNEL INHIBITORS FOR THE TREATMENT OF STROKE AND TRAUMATIC BRAIN INJURY
    Publication number: 20180235959
    Abstract: Described herein are methods of treatment of stroke and traumatic brain injury comprising administration of a CRAC channel inhibitor.
    Type: Application
    Filed: August 5, 2016
    Publication date: August 23, 2018
    Inventors: Kenneth STAUDERMAN, Michael DUNN, Sudarshan HEBBAR, Midori YENARI, Rachid KACIMI